MedTrace Logo

Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT06935994 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-05-11

No results posted yet for this study

Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and/or hepatocellular carcinoma. Although previous evidence suggests that aspirin has antisteatotic and antifibrotic effects on the liver, a randomized controlled trial assessing long-term efficacy and safety of aspirin in MASLD patients has yet to be conducted. This study aims to conduct a randomized controlled trial to evaluate the efficacy of aspirin in treating MASLD.

Conditions

  • Metabolic Dysfunction Associated Steatotic Liver Disease

Interventions

DRUG

Aspirin 81 mg Enteric Coated Tab - 1 tablet

Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo

DRUG

Placebo

Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Principal Investigators

  • Teng-Yu Lee, MD, MBA, PhD · Taichung Veterans General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2028-12-31
Completion
2032-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06935994 on ClinicalTrials.gov